Loss‐of‐function JAK3 mutations in TMD and AMKL of Down syndrome

Summary Acquired mutations activating Janus kinase 3 (jak3) have been reported in Down syndrome (DS) and non‐DS patients with acute megakaryoblastic leukaemia (AMKL). This highlighted jak3‐activation as an important event in the pathogenesis of AMKL, and predicted inhibitors of jak3 as conceptual th...

Full description

Saved in:
Bibliographic Details
Published inBritish journal of haematology Vol. 137; no. 4; pp. 337 - 341
Main Authors De Vita, Serena, Mulligan, Claire, McElwaine, Suzanne, Dagna‐Bricarelli, Franca, Spinelli, Monica, Basso, Giuseppe, Nizetic, Dean, Groet, Jürgen
Format Journal Article
LanguageEnglish
Published Oxford, UK Blackwell Publishing Ltd 01.05.2007
Blackwell
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Summary Acquired mutations activating Janus kinase 3 (jak3) have been reported in Down syndrome (DS) and non‐DS patients with acute megakaryoblastic leukaemia (AMKL). This highlighted jak3‐activation as an important event in the pathogenesis of AMKL, and predicted inhibitors of jak3 as conceptual therapeutics for AMKL. Of 16 DS‐transient myeloproliferative disorder (TMD)/AMKL patients tested, seven showed JAK3 mutations. Three mutations deleted the kinase (JH1) domain, abolishing the main function of jak3. Another patient displayed a mutation identical to a previously reported inherited loss‐of‐function causing severe combined immunodeficiency. Our data suggest that both gain‐, and loss‐of function mutations of jak3 can be acquired in DS‐TMD/AMKL.
ISSN:0007-1048
1365-2141
DOI:10.1111/j.1365-2141.2007.06574.x